PUBLISHER: Coherent Market Insights | PRODUCT CODE: 2078288
PUBLISHER: Coherent Market Insights | PRODUCT CODE: 2078288
Renal Biomarkers Market is estimated to be valued at USD 1,873.2 Mn in 2026 and is expected to reach USD 3,294.4 Mn by 2033, growing at a compound annual growth rate (CAGR) of 8.4% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 1,873.2 Mn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 8.40% | 2033 Value Projection: | USD 3,294.4 Mn |
A biomarker (biologic marker) is a measurable indicator of a specific biological state, particularly one relevant to the risk for, presence of, or stage of a disease. Clinically, biomarkers can be used to screen for, diagnose, or monitor the activity of diseases as well as guide molecularly targeted therapy or assess therapeutic response. Renal biomarkers are biological indicators that help in the diagnosis and monitoring of kidney function and injury. These biomarkers include serum creatinine, blood urea nitrogen, cystatin C, and various urine biomarkers such as albumin, protein, and kidney injury molecule-1 (KIM-1). These biomarkers can be used to identify the early stages of kidney disease, monitor the progression of kidney disease, and predict the risk of kidney injury in patients undergoing medical procedures or taking certain medications. They provide valuable information for healthcare professionals to manage and treat patients with kidney disease, helping to reduce the morbidity and mortality associated with this condition.
The key market players are focusing on the adoption of growth strategies such as product launches which is attributed to the growth of the global renal biomarker market. The renal biomarker market is influenced by several factors such as the increasing prevalence of chronic kidney diseases (CKD), diabetes, and hypertension; the growing aging population; and the rising demand for point-of-care testing. The market is also driven by technological advancements in renal biomarker detection techniques, the increasing number of government initiatives and programs to promote renal health, and the rise in research and development investments in the field. For instance, in April 2021, Renalytix AI plc., a developer of artificial intelligence-enabled clinical in vitro diagnostic solutions for kidney disease, announced that it had entered into an exclusive option agreement with Joslin Diabetes Center, diabetes research, clinical care, and education organization dedicated to the prevention, treatment, and research towards a cure for diabetes, for patent filings on certain additional novel biomarkers in kidney disease for development and deployment in the KidneyIntelX in vitro prognostic platform. These novel biomarkers have the potential to provide additional clinical utility for understanding early disease progression and risk of kidney failure, therapeutic response, and the mechanistic pathways of kidney disease beyond the inflammatory and tubular injury markers that are currently captured by KidneyIntelX.